English
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Taurochenodeoxycholic acid sodium salt
Cholic acid series Products
Taurochenodeoxycholic acid sodium salt.jpg
CAS No.​ 6009-98-9.jpg

Taurochenodeoxycholic acid sodium salt

Taurochenodeoxycholic acid sodium salt is the sodium salt form of taurochenodeoxycholic acid (TCDCA) (CAS: 6009-98-9), with the chemical formula C₂₆H₄₄NO₅SNa and molecular weight 521.69 g/mol. As a stable salt form of conjugated bile acids, it exhibits significantly enhanced water solubility (>500 mg/mL) and is widely used in in vitro diagnostics and pharmaceutical formulations. The United States Pharmacopeia (USP-NF) listed it as a parenteral nutrition additive in 2021, while the European EMA approved it in 2023 for replacement therapy of rare bile acid metabolism disorders (EMA/OD/034/2023).

Product Name: Taurochenodeoxycholic acid sodium salt

CAS No.​: 6009-98-9

Molecular Formula: C₂₆H₄₄NO₅S

    Contact us
    product details
    product description

    description1

    description2

    CAS No

    Basic information

    Product Name: Taurochenodeoxycholic acid sodium salt

    CAS No.​: 6009-98-9

    Molecular Formula: C₂₆H₄₄NO₅S

    IUPAC Name: 2-[[(3α,5β,7α)-3,7-Dihydroxy-24-oxocholan-24-yl]amino]ethanesulfonate sodium

    Appearance & Solubility: 

    Property​

    ​Specification​

    Appearance

    White hygroscopic powder

    Melting Point

    >300°C (decomposition)

    Solubility (25°C)

    Water>500 mg/mL, Ethanol<1 mg/mL

    Surface Tension

    45 mN/m (1% aqueous solution)

    Quality Standard: CP2020,JP,Customer Made

    Specification

    Test Items

    Standard

    Taurochenodeoxycholic acid sodium salt 
    (CAS: 6009-98-9)

    99%

    Key Features

    index_10-7

    Structural Advantage

    Sodium ion binding to sulfonate group (electronegativity difference 1.2, ionic bond energy 42 kcal/mol)

    index_10-7

    Functional Properties

    Critical micelle concentration (CMC) 1.8 mM, superior to glycocholate (3.2 mM)

    30% higher membrane penetration efficiency vs. free acid form

    index_10-7

    Pharmacopoeial Standards

    USP43 requires sodium content 4.2-4.8% (theoretical 4.4%)

    Applications

    Therapeutic Uses​

    Diagnostic Assistance:
    Dynamic bile acid loading test (IV 0.5 mg/kg, 90-min plasma monitoring)
    MRCP contrast enhancer

    Pharmaceutical Formulations: Lipophilic drug solubilizer (e.g., increases paclitaxel loading to 5 mg/mL)

    Industrial Applications​

    Field​

    ​Application​

    ​Technical Parameters​

    Cell Culture

    Primary hepatocyte isolation medium

    Working concentration 0.1-0.5 mM

    Cosmetics

    Transdermal absorption enhancer

    ≤0.3% w/w addition

    Pharmacological Mechanisms

    1.Bile Acid Transport Regulation

    Bile Acid Transport Regulation

    2. Signaling Pathways

    Pathway​

    ​Target​

    ​Potency​

    FXR/RXR

    SHP→CYP7A1 Inhibition

    IC50=8 μM

    EGFR/MAPK

    ↓ERK1/2 Phosphorylation

    40% Inhibition

    Clinical Applications​

    competitiveness2
    competitiveness
    Benefits
    Diagnostic Uses​

    Bile Acid Metabolism Assessment:
    IV infusion 0.1 mg/kg/min×30min with bile acid profiling

    Biliary Imaging Enhancement:
    Oral 1.5 g 2h pre-MRCP
    competitiveness2
    competitiveness
    Benefits
    Therapeutic Uses

    Byler Disease:
    Pediatric oral 50 mg/kg/day in 3 divided doses

    Dosage & Administration

    Formulations​

    Form​

    ​Specification​

    ​Pharmacopoeial Standard​

    Lyophilized Powder

    200mg/vial

    USP<621> Sterility Testing

    Oral Solution

    10% w/v

    EP 11.0 pH 7.0-8.5

    Dosing Regimens​

    Application​

    ​Dose​

    ​PK Parameters​

    Diagnostic Loading Test

    0.5 mg/kg IV

    Tmax=15min, AUC=280 μg·h/mL

    Replacement Therapy

    30-50 mg/kg/day

    Steady-state 12-18 μg/mL

    Safety Profile

    Adverse Reactions​

    System​

    ​Effect (Incidence)​​

    ​Mechanism​

    Cardiovascular

    Bradycardia (3%)

    Cardiac muscarinic receptor activation

    Hepatobiliary

    Transient ALT↑ (8%)

    Hepatocyte membrane permeability alteration

    Drug Interactions​

    Renal Impairment: Dose adjustment required (50% reduction if GFR<30)

    Neonates: Contraindicated (BBB penetration risk)

    Research Progress Green max

    1. Novel Delivery Systems​

    ● Nanosuspensions:
    PVP K30 stabilized (180nm particle size, -35mV zeta potential)

    ● Transdermal Patches:
    Iontophoresis technology (1.2 mg/cm²/24h permeation)

    2.Cutting-Edge Research

    ● Alzheimer's Disease:
    Reduces Aβ40 deposition via BBB penetration (↓30% in animal models)

    ● Cancer Immunotherapy:
    Modulates PD-L1 expression (2× synergy with PD-1 antibodies)

    Taurochenodeoxycholic acid sodium salt

    Please Send me email and you can get more what you want.

    Such as product of  Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.

    Our experts will solve them in no time.